PDF下载 ( 2917 KB)
Guidelines on the diagnosis and management of autoimmune hepatitis (2021)
-
摘要: 自身免疫性肝炎(autoimmune hepatitis, AIH)患者的临床特点包括血清氨基转移酶水平升高、高免疫球蛋白G血症、血清自身抗体阳性, 肝组织学上存在中重度界面性肝炎等。早期诊断和恰当治疗可显著改善AIH患者的生存期和生活质量, 减轻社会医疗负担。《自身免疫性肝炎诊断和治疗共识(2015)》在规范我国AIH的诊断和治疗方面发挥了积极作用。在此基础上, 2021年底中华医学会肝病分会组织有关专家结合最新进展制定本部指南, 旨在进一步提高我国AIH诊治水平。Abstract: Autoimmune hepatitis (AIH) is characterized by elevated serum aminotransferase and immunoglobulin G levels, seropositive results for autoantibodies and moderate to severe interface hepatitis in histologic findings. It will be most helpful in improving survival and life quality, if patients are diagnosed in the early stage and treated appropriately, which also helps relieve social medical burdens. Chinese consensus on the diagnosis and management of autoimmune hepatitis (2015) has contributed to standardizing the diagnosis and treatment of AIH. On the basis of the first consensus, at the end of 2021, under the organization of Chinese Society of Hepatology, experts devise this guide with latest advances aiming to further improve the level of diagnosis and management of autoimmune hepatitis.
-
Key words:
- Hepatitis, Autoimmune /
- Diagnosis /
- Therapeutics /
- Practice Guideline
-
图 1 AIH的药物治疗
注：*建议有条件时在使用前检测TPMT和NUDT15基因型和/或活性, 启动糖皮质激素2周后添加硫唑嘌呤(50~100 mg/d), 并注意监测血常规。失代偿期肝硬化患者不建议使用硫唑嘌呤。* *对于经泼尼松(龙)治疗后副作用严重者, 布地奈德可作为替代药物。但布地奈德在肝硬化患者中失去首过效应的优势, 有增加门静脉血栓形成的风险, 此外在急性重症AIH或急性肝功能衰竭中治疗作用未知, 因此上述情况下不建议使用。
表 1 推荐意见的证据等级和推荐强度等级
级别 详细说明 证据质量 高(A) 进一步研究不可能改变对该疗效评估结果的可信度 中(B) 进一步研究有可能影响该疗效评估结果的可信度, 且可能改变该评估结果 低或非常低(C) 进一步研究很有可能影响该疗效评估结果的可信度, 且很可能改变该评估结果 推荐强度 强(1) 明确显示干预措施利大于弊或弊大于利 弱(2) 利弊不确定或无论质量高低的证据均显示利弊相当 
下载: 导出CSV
表 2 AIH综合诊断积分系统(1999年)
参数/临床特征 计分 参数/临床特征 计分 女性 +2 药物史 ALP(正常上限倍数)与AST(或ALT)(正常上限倍数)的比值 阳性 -4 阴性 +1 ＜1.5 +2 平均乙醇摄入量(g/d) 1.5~3.0 0 ＜25 +2 ＞3.0 -2 ＞60 -2 血清γ-球蛋白或IgG与正常值的比值 肝组织学检查 ＞2.0 +3 界面性肝炎 +3 1.5~2.0 +2 主要为淋巴-浆细胞浸润 +1 1.0~1.5 +1 肝细胞呈玫瑰花环样改变 +1 ＜1.0 0 无上述表现 -5 ANA, ASMA或LKM-1滴度 胆管改变 -3 ＞1∶80 +3 其他改变 -3 1∶80 +2 其他免疫性疾病 +2 1∶40 +1 其他可用的参数 ＜1∶40 0 其他特异性自身抗体(SLA/LP、LC-1、ASGPR、pANCA)阳性 +2 AMA阳性 -4 HLA-DR3或DR4 +1 肝炎病毒标志物 对治疗的反应 阳性 -3 完全 +2 阴性 +3 复发 +3 总积分的解释 治疗前 治疗后 明确的AIH ≥16 明确的AIH ≥18 可能的AIH 10~15 可能的AIH 12~17
下载: 导出CSV
表 3 IAIHG的AIH简化诊断标准
变量 标准 分值 备注 ANA或SMA 1∶40 1 相当于我国常用的ANA 1∶100的最低滴度 ANA或SMA 1∶80 2 多项同时出现时最多2分 LKM-1 1∶40 2 SLA 阳性 2 IgG ＞正常值上限 1 ＞1.1倍正常值上限 2 肝组织学 符合AIH 1 界面性肝炎、汇管区和小叶内淋巴-浆细胞浸润、肝细胞玫瑰样花环以及穿入现象被认为是特征性肝组织学改变, 4项中具备3项为典型表现 典型AIH表现 2 排除病毒性肝炎 是 2 注：分值= 6分：AIH可能；分值≥7分：确诊AIH。
下载: 导出CSV
表 4 AIH的鉴别诊断
疾病 临床表现和实验室检查 病理学表现 HCV感染 血清ANA可低滴度阳性或LKM-1阳性, IgG水平轻度升高；抗-HCV抗体和HCV RNA阳性 肝细胞脂肪变性、淋巴滤泡形成、肉芽肿形成 药物性肝损伤 药物史明确, 停用药物后好转；血清氨基转移酶水平升高和/或胆汁淤积表现 汇管区中性粒细胞和嗜酸粒细胞浸润、肝细胞大泡脂肪变性、肝细胞胆汁淤积, 纤维化程度一般较轻(低于S2) 代谢相关性脂肪性肝病 1/3患者血清ANA可低滴度阳性, 血清氨基转移酶轻度升高, 胰岛素抵抗表现 肝细胞呈大泡脂肪变性、肝窦纤维化、汇管区炎症较轻 Wilson病 血清ANA可阳性, 血清铜蓝蛋白低, 24 h尿铜升高, 可有角膜色素环(K-F环)阳性 存在肝细胞脂肪变性、空泡状核形成、汇管区炎症, 可伴界面炎, 可有大量铜沉着
下载: 导出CSV
-
[1] 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 自身免疫性肝炎诊断和治疗共识(2015)[J]. 临床肝胆病杂志, 2016, 32(1): 9-22. DOI: 10.3969/j.issn.1001-5256.2016.01.002. [2] de BOER YS, GERUSSI A, van den BRAND FF, et al. Association between black race and presentation and liver-related outcomes of patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2019, 17(8): 1616-1624. e2. DOI: 10.1016/j.cgh.2018.11.028. [3] WANG QX, YAN L, MA X. Autoimmune hepatitis in the Asia-Pacific Area[J]. J Clin Transl Hepatol, 2018, 6(1): 48-56. DOI: 10.14218/JCTH.2017.00032. [4] LAMBA M, NGU JH, STEDMAN C. Trends in incidence of autoimmune liver diseases and increasing incidence of autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2021, 19(3): 573-579. e1. DOI: 10.1016/j.cgh.2020.05.061. [5] TANAKA A, MORI M, MATSUMOTO K, et al. Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan[J]. Hepatol Res, 2019, 49(8): 881-889. DOI: 10.1111/hepr.13342. [6] TANAKA A. Autoimmune Hepatitis: 2019 Update[J]. Gut Liver, 2020, 14(4): 430-438. DOI: 10.5009/gnl19261. [7] LI Y, YAN L, WANG R, et al. Serum immunoglobulin G levels predict biochemical and histological remission of autoimmune hepatitis type 1: A single-center experience and literature review[J]. Clin Rev Allergy Immunol, 2021. DOI: 10.1007/s12016-021-08833-w.[Online ahead of print] [8] WANG QX, JIANG WJ, MIAO Q, et al. Clinical and histological features of autoantibody-negative autoimmune hepatitis in Chinese patients: A single center experience[J]. J Dig Dis, 2013, 14(4): 175-180. DOI: 10.1111/1751-2980.12022. [9] DHALIWAL HK, HOEROLDT BS, DUBE AK, et al. Long-term prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis[J]. Am J Gastroenterol, 2015, 110(7): 993-999. DOI: 10.1038/ajg.2015.139. [10] GURUNG A, ASSIS DN, MCCARTY TR, et al. Histologic features of autoimmune hepatitis: A critical appraisal[J]. Hum Pathol, 2018, 82: 51-60. DOI: 10.1016/j.humpath.2018.07.014. [11] MIAO Q, BIAN Z, TANG R, et al. Emperipolesis mediated by CD8 T cells is a characteristic histopathologic feature of autoimmune hepatitis[J]. Clin Rev Allergy Immunol, 2015, 48(2-3): 226-235. DOI: 10.1007/s12016-014-8432-0. [12] STRAVITZ RT, LEFKOWITCH JH, FONTANA RJ, et al. Autoimmune acute liver failure: Proposed clinical and histological criteria[J]. Hepatology, 2011, 53(2): 517-526. DOI: 10.1002/hep.24080 [13] TAKAHASHI A, ARINAGA-HINO T, OHIRA H, et al. Autoimmune hepatitis in Japan: Trends in a nationwide survey[J]. J Gastroenterol, 2017, 52(5): 631-640. DOI: 10.1007/s00535-016-1267-0. [14] ALVAREZ F, BERG PA, BIANCHI FB, et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis[J]. J Hepatol, 1999, 31(5): 929-938. DOI: 10.1016/s0168-8278(99)80297-9. [15] HENNES EM, ZENIYA M, CZAJA AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis[J]. Hepatology, 2008, 48(1): 169-176. DOI: 10.1002/hep.22322. [16] QIU D, WANG Q, WANG H, et al. Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients[J]. J Hepatol, 2011, 54(2): 340-347. DOI: 10.1016/j.jhep.2010.06.032. [17] GALASKI J, WEILER-NORMANN C, SCHAKAT M, et al. Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing[J]. J Hepatol, 2021, 74(2): 312-320. DOI: 10.1016/j.jhep.2020.07.032. [18] CHEN RL, WANG QX, MA X. Precision medicine for autoimmune hepatitis[J]. J Dig Dis, 2019, 20(7): 331-337. DOI: 10.1111/1751-2980.12786. [19] WANG Z, SHENG L, YANG Y, et al. The management of autoimmune hepatitis patients with decompensated cirrhosis: Real-world experience and a comprehensive review[J]. Clin Rev Allergy Immunol, 2017, 52(3): 424-435. DOI: 10.1007/s12016-016-8583-2. [20] PEISELER M, LIEBSCHER T, SEBODE M, et al. Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2018, 16(2): 260-267. e1. DOI: 10.1016/j.cgh.2016.12.040. [21] MANNS MP, WOYNAROWSKI M, KREISEL W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis[J]. Gastroenterology, 2010, 139(4): 1198-1206. DOI: 10.1053/j.gastro.2010.06.046. [22] WOYNAROWSKI M, NEMETH A, BARUCH Y, et al. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents[J]. J Pediatr, 2013, 163(5): 1347-1353. e1. DOI: 10.1016/j.jpeds.2013.05.042. [23] EFE C, HAGSTRÖM H, YTTING H, et al. Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2017, 15(12): 1950-1956. e1. DOI: 10.1016/j.cgh.2017.06.001. [24] LIBERAL R, de BOER YS, ANDRADE RJ, et al. Expert clinical management of autoimmune hepatitis in the real world[J]. Aliment Pharmacol Ther, 2017, 45(5): 723-732. DOI: 10.1111/apt.13907. [25] DE LEMOS-BONOTTO M, VALLE-TOVO C, COSTABEBER AM, et al. A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment[J]. Eur J Gastroenterol Hepatol, 2018, 30(2): 212-216. DOI: 10.1097/MEG.0000000000001019. [26] HANOUNEH M, RITCHIE MM, ASCHA M, et al. A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis[J]. Scand J Gastroenterol, 2019, 54(1): 76-80. DOI: 10.1080/00365521.2018.1551498. [27] MONTANO-LOZA AJ, BHANJI RA, WASILENKO S, et al. Systematic review: Recurrent autoimmune liver diseases after liver transplantation[J]. Aliment Pharmacol Ther, 2017, 45(4): 485-500. DOI: 10.1111/apt.13894. [28] MACK CL, ADAMS D, ASSIS DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases[J]. Hepatology, 2020, 72(2): 671-722. DOI: 10.1002/hep.31065. [29] KERKAR N, YANNI G. 'De novo' and 'recurrent' autoimmune hepatitis after liver transplantation: A comprehensive review[J]. J Autoimmun, 2016, 66: 17-24. DOI: 10.1016/j.jaut.2015.08.017. [30] MORIYAMA T, NISHⅡ R, PEREZ-ANDREU V, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity[J]. Nat Genet, 2016, 48(4): 367-373. DOI: 10.1038/ng.3508. [31] LOHSE AW, SEBODE M, J∅RGENSEN MH, et al. Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group[J]. J Hepatol, 2020, 73(6): 1496-1506. DOI: 10.1016/j.jhep.2020.07.023. [32] XU Q, SHENG L, BAO H, et al. Evaluation of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis[J]. J Gastroenterol Hepatol, 2017, 32(3): 639-644. DOI: 10.1111/jgh.13508. [33] HARTL J, EHLKEN H, SEBODE M, et al. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis[J]. J Hepatol, 2018, 68(4): 754-763. DOI: 10.1016/j.jhep.2017.11.020. [34] FIX OK, BLUMBERG EA, CHANG KM, et al. American Association for the Study of Liver Diseases Expert Panel consensus statement: Vaccines to prevent coronavirus disease 2019 infection in patients with liver disease[J]. Hepatology, 2021, 74(2): 1049-1064. DOI: 10.1002/hep.31751. [35] CORNBERG M, BUTI M, EBERHARDT CS, et al. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients[J]. J Hepatol, 2021, 74(4): 944-951. DOI: 10.1016/j.jhep.2021.01.032. [36] BIEWENGA M, INDERSON A, TUSHUIZEN ME, et al. Early predictors of short-term prognosis in acute and acute severe autoimmune hepatitis[J]. Liver Transpl, 2020, 26(12): 1573-1581. DOI: 10.1002/lt.25906. [37] ZACHOU K, ARVANITI P, AZARIADIS K, et al. Prompt initiation of high-dose i. v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis[J]. Hepatol Res, 2019, 49(1): 96-104. DOI: 10.1111/hepr.13252. [38] YEOMAN AD, WESTBROOK RH, ZEN Y, et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): The role of corticosteroids in modifying outcome[J]. J Hepatol, 2014, 61(4): 876-882. DOI: 10.1016/j.jhep.2014.05.021. [39] REDDY HG, SCHNEIDER BJ, TAI AW. Immune checkpoint inhibitor-associated colitis and hepatitis[J]. Clin Transl Gastroenterol, 2018, 9(9): 180. DOI: 10.1038/s41424-018-0049-9. [40] CZAJA AJ. Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis[J]. Autoimmunity, 2019, 52(4): 144-160. DOI: 10.1080/08916934.2019.1641200. [41] LOOMBA R, LIANG TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: Current concepts, management strategies, and future directions[J]. Gastroenterology, 2017, 152(6): 1297-1309. DOI: 10.1053/j.gastro.2017.02.009. [42] LIN XQ, SHENG L, XIAO X, et al. Analysis of clinical diagnosis and treatment in chronic hepatitis B combined with autoimmune hepatitis[J]. Chin J Hepatol, 2020, 28(4): 351-356. DOI: 10.3760/cma.j.cn501113-20190120-00020.林小钦, 盛黎, 肖潇, 等. 慢性乙型肝炎合并自身免疫性肝炎的临床诊治分析[J]. 中华肝脏病杂志, 2020, 28(4): 351-356. DOI: 10.3760/cma.j.cn501113-20190120-00020. [43] MIELI-VERGANI G, VERGANI D, BAUMANN U, et al. Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN hepatology committee position statement[J]. J Pediatr Gastroenterol Nutr, 2018, 66(2): 345-360. DOI: 10.1097/MPG.0000000000001801. [44] NASTASIO S, SCIVERES M, MATARAZZO L, et al. Long-term follow-up of children and young adults with autoimmune hepatitis treated with cyclosporine[J]. Dig Liver Dis, 2019, 51(5): 712-718. DOI: 10.1016/j.dld.2018.10.018. [45] EFE C, TAⅡ HA, YTTING H, et al. Tacrolimus and mycophenolate mofetil as second-line therapies for pediatric patients with autoimmune hepatitis[J]. Dig Dis Sci, 2018, 63(5): 1348-1354. DOI: 10.1007/s10620-018-5011-x. [46] WANG Q, QIU D, MA X. Early normalisation of aminotransferase predicts complete biochemical remission in autoimmune hepatitis patients[J]. Aliment Pharmacol Ther, 2011, 34(1): 107-109. DOI: 10.1111/j.1365-2036.2011.04690.x. [47] TANSEL A, KATZ LH, EL-SERAG HB, et al. Incidence and determinants of hepatocellular carcinoma in autoimmune hepatitis: A systematic review and Meta-analysis[J]. Clin Gastroenterol Hepatol, 2017, 15(8): 1207-1217. e4. DOI: 10.1016/j.cgh.2017.02.006. -
本文二维码
图(1) / 表(4)
计量
- 文章访问数: 6020
- HTML全文浏览量: 579
- PDF下载量: 1819
- 被引次数: 0
